HIV treatment study


Title: A5391: Doravirine for Persons with Excessive Weight Gain while taking Integrase Inhibitors and Tenofovir Alafenamide (TAF): The DO-IT Study Click here for printable participant summary. Description: Weight gain after starting anti-HIV medicines is common, but recent studies have found that taking certain medicines may cause increased weight more than […]

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase ...   Recently updated !


Title: A5386: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control in the Reservoirs During Analytic Treatment Interruption Purpose: Researchers are looking for ways to get rid of HIV that rests hidden in areas of the body (reservoirs) where current […]

A5386, a clinical trial to control HIV in a new ...   Recently updated !



Title: A5379 BEEHIVE B-Enhancement of HBV Vaccination in Persons Living with HIV (BEe-HIVe) Description Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. Although there is a vaccination for hepatitis B, sometimes the vaccines do not work well for people […]

A5379: BEEHIVE, a Hepatitis-B Vaccine Study for People Living with ...


Title: AIDS 392: TRAILBLAZER, elimination of CCR5 receptors with zinc finger to prevent viral replication, in participants living with HIV Purpose: The main purpose of this study is to test a new type of strategy to treat HIV: giving people living with HIV genetically modified versions of their own CD4+ […]

AIDS 392: TRAILBLAZER, elimination of CCR5 receptors with zinc finger ...



Protocol Summary: Trio (ACTG5377) is a Phase I, first-in-human, ascending-dose study of a tri-specific broadly neutralizing antibody, in participants living with HIV. This trial will look at a human-made antibody called SAR441236. Unlike the antibodies created by a person’s immune system that attach to HIV at one part, SAR441236 has […]

Trio A5377: A Phase I, first-in-human, ascending-dose study of a ...